P-062 QUINTESSENTIAL: A Multicenter Phase 2 Study Evaluating the Efficacy and Safety of BMS-986393 in Patients With Quadruple-Class Exposed Relapsed or Refractory Multiple Myeloma
Krina K. Patel(University of Vermont), Susan Bal(University of Alabama at Birmingham Hospital), Tara Gregory(Colorado Blood Cancer Institute), Omar Nadeem(Harvard University), Tim Pulham(Bristol-Myers Squibb (United States)), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Paola Neri(University of Calgary), Hongxiang Hu(Bristol-Myers Squibb (United States)), Shinsuke Iida(Nagoya City University Hospital), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Sarah Johnston(Bristol-Myers Squibb (United States)), Nikhil Munshi, Svenja Groeneveld(Bristol-Myers Squibb (United States)), Jaclyn Davis(Bristol-Myers Squibb (United States)), Julia Piasecki(Université Paris Cité), Sarah Larson(UCLA Medical Center)
Cited by 0
Related Papers
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430